A review about cannabis use like as risk factor of schizophrenia;Revisión sobre el consumo de cannabis como factor de riesgo de la esquizofrenia

Adicciones

Volumn 19, Issue 2, 2007, Pages 191-203

  Horcajadas, Francisco Arias ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Cannabis; Psychosis; Risk factor; Schizophrenia; Vulnerability

Indexed keywords

CANNABIS;

CANNABIS ADDICTION; COHORT ANALYSIS; CONFUSION; HIGH RISK POPULATION; HUMAN; PREVENTION AND CONTROL; PSYCHOSIS; PSYCHOSOCIAL ENVIRONMENT; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

EID: 34347353398     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.316     Document Type: Review

References (80)

1. Andreasson, S., Allebeck, P., Engstrom, A. y Rydberg U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2, 1483-1486.
2. Arendt, M. y Munk-Jorgensen, P. (2004). Heavy cannabis users seeking treatment-prevalence of psychiatric disorders. Social Psychiatry and Psychiatric Epidemiology, 39, 97-105.
3. Arendt, M., Rosenberg, R., Foldager, L., Perto, G. y Munk-Jorgensen, R (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry, 187, 510-515.
4. Arguello, P.A. y Jentsch, J.D. (2004). Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berlin), 177, 141-150.
5. Arias, F., Sánchez, S. y Padín, J.J. (2002a). Relevancia del consumo de drogas en las manifestaciones clínicas de la esquizofrenia. Actas Españolas de Psiquiatría, 30, 65-73.
6. Arias, F., Sánchez, S. y Padín, J.J. (2002b). Consumo de drogas y riesgo de recaída en la esquizofrenia. Psiquiatría Biológica, 9, 63-67.
7. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A. y Moffitt, T.E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal, 325, 1212-1213.
8. Arseneault, L., Cannon, M., Witton, J. y Murray, R.M. (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry, 184, 110-117.
9. Batel, P. (2000). Addiction and schizophrenia. European Psychiatry, 15, 115-122.
10. Barnes, T.R., Mutsatsa, S.H., Hutton, S.B., Watt, H.C. y Joyce, E.M. (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry, 188, 237-242.
11. Bersani, G., Orlandi, V., Gherardelli, S. y Pancheri, P. (2002). Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology, 35, 289-295.
12. Buhler, B., Hambrecht, M., Loffler, W., van der Heiden, W. y Hafner, H. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research, 54, 243-251.
13. Caspari, D. (1999). Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neurosciences, 249, 45-49.
14. Caspi, A., Moffitt, T.E., Cannon, M., McClay, J., Murray, R. y Harrington, H., et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57, 1117-1127
15. Caton, C.L., Drake, R.E., Hasin, D.S., Dominguez, B., Shrout, P.E. y Samet, S., et al. (2005). Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry, 62, 137-145.
16. Chaudry, H.R., Moss, H.B., Bashir, A. y Suliman, T. (1991). Cannabis psychosis following bhang ingestion. British Journal of Addiction, 86, 1075-1081.
17. Chopra, G.S. y Smith, J.W. (1974). Psychotic reactions following cannabis use in East Indians. Archives of General Psychiatry, 30, 24-27.
18. Compton, M.T., Furman, A.C. y Kaslow, N.J. (2004). Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophrenia Research, 71, 61-64.
19. Dean, B., Sundram, S., Bradbury, R., Scarr, E. y Copolov, D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103, 9-15.
20. Degenhardt, L. (2003). The link between cannabis use and psychosis: furthering the debate. Psychological Medicine, 33, 3-6.
21. De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F. y Di Marzo, V. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Diseases, 2, 5.
22. DeQuardo, J.R., Carpenter, C.F. y Tandon, R. (1994). Patterns of substance abuse in schizophrenia: Nature and significance. Journal of Psychiatric Research, 28, 267-275.
23. Dubertret, C., Bidard, I., Ades, J. y Gorwood, P. (2006). Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research, 86; 284-290.
24. D'Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T. y Wu, Y.T., et al. (2004).The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
25. D'Souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch, A. y Braley, G., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry, 57, 594-608.
26. Emrich, H.M., Leweke, F.M. y Schneider, U. (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology, Biochemistry, and Behavior, 56, 803-807.
27. Favrat, B., Menetrey, A., Augsburger, M., Rothuizen, L.E., Appenzeller, M. y Buclin, T., et al. (2005). Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry, 5, 17.
28. Fergusson, D.M., Horwood, L.J. y Swain-Campbell, N.R. (2003). Cannabis dependence and psychotic symptoms in young people. Psychological Medicine, 33, 15-21.
29. Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D. y Faulhaber, J., et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29, 2108-2114.
30. Green, A.I., Tohen, M.F., Hamer, R.M., Strakowski, S.M., Lieberman, J.A. y Glick, I., et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research, 66, 125-135.
31. Green, B., Young, R. y Kavanagh, D. (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry, 187, 306-313.
32. Hall, W. (2006). Is cannabis use psychotogenic? Lancet, 367, 193-195.
33. Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R. y Wittchen, H.U., et al. (2005a). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal, 330, 11.
34. Henquet, C., Murray, R., Linszen, D. y van Os, J. (2005b). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin, 31, 608-612.
35. Hunt, G.E., Bergen, J. y Bashir, M. (2002). Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophrenia Research, 54, 253-264.
36. Irala, J., Ruiz-Canela, M. y Martínez-González, M.A. (2005). Causal relationship between cannabis use and psychotic symptoms or depression. Should we wait and see? A public health perspective. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 11, 355-358.
37. Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A. y Cooper, J.E., et al. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, Monograph Suppl. 20, 1-97.
38. Jiménez, D., Sánchez, S., Zazo, J., Arias, F. y Soto, A. (pendiente de publicación). Ingresos de inmigrantes en una unidad de hospitalización psiquiátrica breve. Anales de Psiquiatría..
39. Kavanagh, D.J., Waghorn, G., Jenner, L., Chant, D.C., Carr, V. y Evans, M., et al. (2004). Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research, 66, 115-124.
40. Kumra, S., Thaden, E., DeThomas, C. y Kranzler, H. (2005). Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophrenia Research, 73, 369-371.
41. Leweke, F.M., Schneider, U., Radwan, M., Schmidt, E. y Emrich, H.M. (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacology, Biochememistry, and Behavior, 66, 175-181.
42. Leweke, F.M., Gerth, C.W. y Klosterkotter, J. (2004). Cannabis-associated psychosis: current status of research. CNS Drugs, 18, 895-910.
43. Linszen, D.H., Dingemans, P.M. y Lenior, M.E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51, 273-279.
44. Luaute, J.P. (2004). Cannabis and psychosis. British Journal of Psychiatry, 185, 352-353 (letter).
45. Macleod, J., Oakes, R., Copello, A., Crome, I., Egger, M. y Hickman, M., et al. (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet, 363, 1579-1588.
46. Margolese, H.C., Negrete, J.C., Tempier, R. y Gill, K. (2006). A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophrenia Research, 83, 65-75.
47. McGuire, P.K., Jones, P., Harvey, I., Bebbington, P., Toone, B. y Lewis, S., et al. (1994). Cannabis and acute psychosis. Schizophrenia Research, 13, 161-167.
48. Nuñez, L.A. y Gurpegui, M. (2002). Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica, 105, 173-178.
49. Potvin, S., Sepehry, A.A. y Stip, E. (2006). A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine, 36, 431-440.
50. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J. y Judd, L.L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of American Medical Association, 264, 2511-2518.
51. Rey, J.M. y Tennant, C.C. (2002). Cannabis and mental health. More evidence establishes clear link between use of cannabis and psychiatric illness. British Medical Journal, 325, 1183-1184.
52. Rottanburg, D., Robins, A.H., Ben-Arie, O., Teggin, A. y Elk, R. (1982). Cannabis-associated psychosis with hypomanic features. Lancet, 2, 1364-1366.
53. Schiffman, J., Nakamura, B., Earleywine, M. y LaBrie, J. (2005). Symptoms of schizotypy precede cannabis use. Psychiatry Research, 134, 37-42.
54. Semple, D.M., McIntosh, A.M. y Lawrie, S.M. (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology, 19, 187-194.
55. Shakir, S.A. y Layton, D. (2002). Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Safety, 25: 467-471.
56. Skosnik, P.D., Spatz-Glenn, L. y Park, S. (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research, 48, 83-92.
57. Smit, F., Bolier, L. y Cuijpers, P. (2004). Cannabis use and the risk of later schizophrenia: a review. Addiction, 99, 425-430.
58. Steffens, M., Engler, C., Zentner, J. y Feuerstein, T.J. (2004). Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. British Journal of Pharmacology, 141, 1193-1203.
59. Stellman, S.D., Takezaki, T., Wang, L., Chen, Y., Citron, M.L. y Djordjevic, M.V., et al. (2001). Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiology, Biomarkers and Prevention, 10, 1193-1199.
60. Swartz, M.S., Wagner, H.R., Swanson, J.W., Stroup, T.S., McEvoy, J.P. y Canive, J.M., et al. (2006). Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Diseases, 194, 164-172.
61. Talamo, A., Centorrino, F., Tondo, L., Dimitri, A., Hennen, J. y Baldessarini, R.J. (2006). Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophrenia Research, 86, 251-255.
62. Talbott, J.A. y Teague, J.W. (1969). Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. Journal of American Medical Association, 210, 299-302.
63. Tanda, G., Pontieri, F.E. y Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science, 276, 2048-2050.
64. Tennant, F.S. Jr y Groesbeck, C.J. (1972). Psychiatric effects of hashish. Archives of General Psychiatry, 27: 133-136.
65. Tien, A.Y. y Anthony, J.C. (1990). Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. Journal of Nervous and Mental Diseases, 178, 473-480.
66. Thacore, V.R. y Shukla, S.R. (1976). Cannabis psychosis and paranoid schizophrenia. Archives of General Psychiatry, 33, 383-386.
67. Thomas, H. (1996). A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence, 42, 201-207.
68. Tramer, M.R., Carroll, D., Campbell, F.A., Reynolds, D.J., Moore, R.A. y McQuay, H.J. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. British Medical Journal, 323, 16-21.
69. Treffert, D.A. (1978). Marijuana use in schizophrenia: a clear hazard. American Journal of Psychiatry, 135, 1213-1215.
70. Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T. y Kodama, M., et al. (2002). CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Molecular Psychiatry, 7, 515-518.
71. Van Mastrigt, S., Addington, J. y Addington, D. (2004). Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology, 39, 69-72.
72. Van Os, J., Bak, M., Hanssen, M., Bijl, R.V., de Graaf, R. y Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology, 156, 319-327
73. Veen, N.D., Selten, J.P., van der Tweel, I., Feller, W.G., Hoek, H.W. y Kahn, R.S. (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry, 161, 501-506.
74. Verdoux, H., Gindre, C., Sorbara, F., Tournier, M. y Swendsen, J.D. (2003). Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine, 33, 23-32.
75. Verdoux, H., Tournier, M. y Cougnard, A. (2005). Impact of substance use on the onset and course of early psychosis. Schizophrenia Research, 79, 69-75.
76. Voruganti, L.N., Slomka, P., Zabel, P., Mattar, A. y Awad, A.G. (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research, 107, 173-177
77. Wade, D. (2005). Cannabis use and schizophrenia. American Journal of Psychiatry, 162, 401.
78. Weiser, M., Knobler, H.Y., Noy, S. y Kaplan, Z. (2002). Clinical characteristics of adolescents later hospitalized for schizophrenia. American Journal of Medical Genetics, 114: 949-955.
79. Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. y Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal, 325, 1199.
80. Zavitsanou, K., Garrick, T. y Huang, X.F. (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry, 28, 355-360.